Role of lower dose hepatitis B immune globulin prophylaxis in liver transplantation: A single center perspective
Prevention of hepatitis B virus (HBV) reinfection is important for long-term outcomes following liver transplantation (LT). Hepatitis B immunoglobulin (HBIG) is used among recipients who have (i) native HBV disease, (ii) hepatitis B core antibody positivity (HBcAb positivity), or (iii) received HBcA...
Saved in:
Published in | Hepatology Forum Vol. 4; no. 1; pp. 3 - 6 |
---|---|
Main Authors | , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Turkey
Kare Publishing
01.01.2023
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Prevention of hepatitis B virus (HBV) reinfection is important for long-term outcomes following liver transplantation (LT). Hepatitis B immunoglobulin (HBIG) is used among recipients who have (i) native HBV disease, (ii) hepatitis B core antibody positivity (HBcAb positivity), or (iii) received HBcAb positive organs. Nucleos(t)ide analogue (NA) monotherapy is emerging for treating patients in this setting. There is no generalized consensus on the ideal dosage of HBIG. The aim of this study was to evaluate the efficacy of low-dose HBIG (1560 international unit [IU]) for post-LT HBV prevention.
HBcAb positive patients who received either HBcAb positive or hepatitis B core antibody negative (HBcAb negative) organs and HBcAb negative patients who received HBcAb positive organs between January 2016 and December 2020 were reviewed. Pre-LT HBV serologies were collected. HBV-prophylaxis strategy included NA with/without HBIG. HBV recurrence was defined as HBV deoxyribonucleic acid (DNA) positivity during the 1-year, post-LT follow-up. No HBV surface antibody titers were followed.
A total of 103 patients with a median age of 60 years participated in the study. Hepatitis C virus was the most common etiology. Thirty-seven HBcAb negative recipients and 11 HBcAb positive recipients with undetectable HBV DNA received HBcAb positive organs and underwent prophylaxis with 4 doses of low-dose HBIG and NA. None of the recipients in our cohort had a recurrence of HBV at 1 year.
Low-dose HBIG (1560 IU) × 4 days and NA, for HBcAb positive recipients and HBcAb positive donors, appear to be effective in preventing HBV reinfection during the post-LT period. Further trials are needed to confirm this observation. |
---|---|
AbstractList | Prevention of hepatitis B virus (HBV) reinfection is important for long-term outcomes following liver transplantation (LT). Hepatitis B immunoglobulin (HBIG) is used among recipients who have (i) native HBV disease, (ii) hepatitis B core antibody positivity (HBcAb positivity), or (iii) received HBcAb positive organs. Nucleos(t)ide analogue (NA) monotherapy is emerging for treating patients in this setting. There is no generalized consensus on the ideal dosage of HBIG. The aim of this study was to evaluate the efficacy of low-dose HBIG (1560 international unit [IU]) for post-LT HBV prevention.
HBcAb positive patients who received either HBcAb positive or hepatitis B core antibody negative (HBcAb negative) organs and HBcAb negative patients who received HBcAb positive organs between January 2016 and December 2020 were reviewed. Pre-LT HBV serologies were collected. HBV-prophylaxis strategy included NA with/without HBIG. HBV recurrence was defined as HBV deoxyribonucleic acid (DNA) positivity during the 1-year, post-LT follow-up. No HBV surface antibody titers were followed.
A total of 103 patients with a median age of 60 years participated in the study. Hepatitis C virus was the most common etiology. Thirty-seven HBcAb negative recipients and 11 HBcAb positive recipients with undetectable HBV DNA received HBcAb positive organs and underwent prophylaxis with 4 doses of low-dose HBIG and NA. None of the recipients in our cohort had a recurrence of HBV at 1 year.
Low-dose HBIG (1560 IU) × 4 days and NA, for HBcAb positive recipients and HBcAb positive donors, appear to be effective in preventing HBV reinfection during the post-LT period. Further trials are needed to confirm this observation. Background and AimPrevention of hepatitis B virus (HBV) reinfection is important for long-term outcomes following liver transplantation (LT). Hepatitis B immunoglobulin (HBIG) is used among recipients who have (i) native HBV disease, (ii) hepatitis B core antibody positivity (HBcAb positivity), or (iii) received HBcAb positive organs. Nucleos(t)ide analogue (NA) monotherapy is emerging for treating patients in this setting. There is no generalized consensus on the ideal dosage of HBIG. The aim of this study was to evaluate the efficacy of low-dose HBIG (1560 international unit [IU]) for post-LT HBV prevention. Materials and MethodsHBcAb positive patients who received either HBcAb positive or hepatitis B core antibody negative (HBcAb negative) organs and HBcAb negative patients who received HBcAb positive organs between January 2016 and December 2020 were reviewed. Pre-LT HBV serologies were collected. HBV-prophylaxis strategy included NA with/without HBIG. HBV recurrence was defined as HBV deoxyribonucleic acid (DNA) positivity during the 1-year, post-LT follow-up. No HBV surface antibody titers were followed. ResultsA total of 103 patients with a median age of 60 years participated in the study. Hepatitis C virus was the most common etiology. Thirty-seven HBcAb negative recipients and 11 HBcAb positive recipients with undetectable HBV DNA received HBcAb positive organs and underwent prophylaxis with 4 doses of low-dose HBIG and NA. None of the recipients in our cohort had a recurrence of HBV at 1 year. ConclusionLow-dose HBIG (1560 IU) × 4 days and NA, for HBcAb positive recipients and HBcAb positive donors, appear to be effective in preventing HBV reinfection during the post-LT period. Further trials are needed to confirm this observation. |
Author | Edwards, Diep Wesson, Russel Gurakar, Ahmet Lin, Jessica Dao, Doan Pustavoitau, Aliaksei Toman, Lindsey Kohli, Ruhail Ottmann, Shane E Gurakar, Merve Kim, Ahyoung |
Author_xml | – sequence: 1 givenname: Diep surname: Edwards fullname: Edwards, Diep organization: Department of Internal Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA – sequence: 2 givenname: Jessica surname: Lin fullname: Lin, Jessica organization: Division of Gastroenterology and Hepatology, Transplant Hepatology, Johns Hopkins University School of Medicine, Baltimore, MD, USA – sequence: 3 givenname: Lindsey surname: Toman fullname: Toman, Lindsey organization: Department of Pharmacy, Johns Hopkin Hospital, Baltimore, MD, USA – sequence: 4 givenname: Merve surname: Gurakar fullname: Gurakar, Merve organization: Division of Gastroenterology and Hepatology, Transplant Hepatology, Johns Hopkins University School of Medicine, Baltimore, MD, USA – sequence: 5 givenname: Aliaksei surname: Pustavoitau fullname: Pustavoitau, Aliaksei organization: Department of Anesthesiology, Johns Hopkins University School of Medicine, Baltimore, MD, USA – sequence: 6 givenname: Ruhail surname: Kohli fullname: Kohli, Ruhail organization: Division of Gastroenterology and Hepatology, Transplant Hepatology, Johns Hopkins University School of Medicine, Baltimore, MD, USA – sequence: 7 givenname: Russel surname: Wesson fullname: Wesson, Russel organization: Division of Transplant Surgery, Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA – sequence: 8 givenname: Shane E surname: Ottmann fullname: Ottmann, Shane E organization: Division of Transplant Surgery, Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA – sequence: 9 givenname: Doan surname: Dao fullname: Dao, Doan organization: Division of Gastroenterology and Hepatology, Transplant Hepatology, Johns Hopkins University School of Medicine, Baltimore, MD, USA – sequence: 10 givenname: Ahmet surname: Gurakar fullname: Gurakar, Ahmet organization: Division of Gastroenterology and Hepatology, Transplant Hepatology, Johns Hopkins University School of Medicine, Baltimore, MD, USA – sequence: 11 givenname: Ahyoung surname: Kim fullname: Kim, Ahyoung organization: Division of Gastroenterology and Hepatology, Transplant Hepatology, Johns Hopkins University School of Medicine, Baltimore, MD, USA |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/36843892$$D View this record in MEDLINE/PubMed |
BookMark | eNpVUctu1TAQtVARvX38AAvkZTcpfiSx3UWlUlFAqoSE2rXlJJMbI8d27aTQv8e3t1SwmdHoPGZG5wgd-OABofeUnNNa1PXHaTxnhLF9IYSTN2jDRCMqwRU7QBvKiagaKeUhOs35JyGESUpoS9-hQ97KmkvFNij-CA5wGLELvyDhIWTAE0Sz2MVm_AnbeV494K0L3eqsxzGFOD0587ugZXT2saiWZHyOzvil6IK_wFc4W78txj34pRAipByhXwr7BL0djctw-tKP0f3N57vrr9Xt9y_frq9uq543fKla0QnDlemkbFjPBKM9NbIdFCdUNh3ruOqZagY2csF4J1Xb8HowIIF2NRHAj9Hl3jeu3QzD7pBknI7JziY96WCs_h_xdtLb8KiVaqhUshicvRik8LBCXvRscw-uvAlhzZoJSWrJFBWFyvbUPoWcE4yvayjRz2npadS7oPZll1YRffj3wFfJ32z4H-stlGo |
ContentType | Journal Article |
Copyright | Copyright 2023 by Hepatology Forum. Copyright 2023 by Hepatology Forum 2023 |
Copyright_xml | – notice: Copyright 2023 by Hepatology Forum. – notice: Copyright 2023 by Hepatology Forum 2023 |
DBID | NPM AAYXX CITATION 7X8 5PM |
DOI | 10.14744/hf.2022.2022.0030 |
DatabaseName | PubMed CrossRef MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | PubMed CrossRef MEDLINE - Academic |
DatabaseTitleList | PubMed MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
EISSN | 2757-7392 |
EndPage | 6 |
ExternalDocumentID | 10_14744_hf_2022_2022_0030 36843892 |
Genre | Journal Article |
GroupedDBID | 7X7 8FI 8FJ ABUWG AFKRA ALIPV ALMA_UNASSIGNED_HOLDINGS BENPR CCPQU EN8 FYUFA HMCUK IAO IHR INH ITC NPM PIMPY RPM UKHRP AAYXX CITATION M~E 7X8 5PM |
ID | FETCH-LOGICAL-c353t-67b7a39ab8852c2721c1a86d930185b2b39c295d2f3723b896534dae8e1b407e3 |
IEDL.DBID | RPM |
ISSN | 1307-5888 |
IngestDate | Tue Sep 17 21:32:24 EDT 2024 Sat Jun 22 20:27:48 EDT 2024 Fri Aug 23 00:55:37 EDT 2024 Sat Sep 28 08:15:31 EDT 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Keywords | HBIG HBV liver transplantation |
Language | English |
License | Copyright 2023 by Hepatology Forum. This work is licensed under a Creative Commons Attribution-Non Commercial 4.0 International License (CC BY-NC 4.0) |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c353t-67b7a39ab8852c2721c1a86d930185b2b39c295d2f3723b896534dae8e1b407e3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9951898/ |
PMID | 36843892 |
PQID | 2780482917 |
PQPubID | 23479 |
PageCount | 4 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_9951898 proquest_miscellaneous_2780482917 crossref_primary_10_14744_hf_2022_2022_0030 pubmed_primary_36843892 |
PublicationCentury | 2000 |
PublicationDate | 2023-01-01 |
PublicationDateYYYYMMDD | 2023-01-01 |
PublicationDate_xml | – month: 01 year: 2023 text: 2023-01-01 day: 01 |
PublicationDecade | 2020 |
PublicationPlace | Turkey |
PublicationPlace_xml | – name: Turkey |
PublicationTitle | Hepatology Forum |
PublicationTitleAlternate | Hepatol Forum |
PublicationYear | 2023 |
Publisher | Kare Publishing |
Publisher_xml | – name: Kare Publishing |
SSID | ssj0002810161 ssib050732170 |
Score | 2.2584887 |
Snippet | Prevention of hepatitis B virus (HBV) reinfection is important for long-term outcomes following liver transplantation (LT). Hepatitis B immunoglobulin (HBIG)... Background and AimPrevention of hepatitis B virus (HBV) reinfection is important for long-term outcomes following liver transplantation (LT). Hepatitis B... |
SourceID | pubmedcentral proquest crossref pubmed |
SourceType | Open Access Repository Aggregation Database Index Database |
StartPage | 3 |
Title | Role of lower dose hepatitis B immune globulin prophylaxis in liver transplantation: A single center perspective |
URI | https://www.ncbi.nlm.nih.gov/pubmed/36843892 https://search.proquest.com/docview/2780482917 https://pubmed.ncbi.nlm.nih.gov/PMC9951898 |
Volume | 4 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3fS-QwEB5cn3wR5U5dPSWCb1J3m19NffNEkYMVEQXfStKk7EJtF7cLPt3f7ky7u-eeb74EStI0TCedmfSbbwDOvHJSWI37G21fJIPKI8MLH0lnguapLgSnbOTRvb57ln9e1MsGqGUuTAvaz93koipfL6rJuMVWTl_zwRInNngYXafoFpjUDHrQQ_O7HqKjfyPQzR6uDlo4UVh1vKlEiKgw5Fskz8hEysGYeDw575phi4b-bKC-eJ3_gyc_WaPbHdheuJHsqlvuLmyE6gdMH-sysLpgJZU-Y76eBTYOBJluJjP2m00oFyQw4gAh_DnDp6KQS_uOvXhZEkSDNS3beWm7lKTqkl0xOk7AiWkpOGD6Lz3zJzzf3jxd30WLigpRLpRoIp24xIrUOmMUzzlGf3lsjfYpbnOjHHcizXmqPC9EwoUzqVZCehtMiB1GfkHswWZVV-EAWGxDsIm3nlsjYxtbjHbN0BY69w6_WbYP50sxZtOOOCOjgIOEno2LjOTdNST0PpwuJZ2hftNPC1uFej7LODEkGY5RZR_2O8mv5hPaUPF23odk7Z2sBhB39noPqlTLob1QocNv33kEW1R5vjuN-QWbzds8HKN_0rgT6I3-3py0WvkBuwLm9A |
link.rule.ids | 230,314,727,780,784,885,27924,27925,53791,53793 |
linkProvider | National Library of Medicine |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3fT9swED4x9sBepqGNrWMMI-1tCm38KzZvDIG6QdE0gcRbZMeOWikkFQ3S_vzdJW1HtzdeLEV2HOtyju8u330H8CUoL4XTuL_x7EtkVEVieBkS6U3U3OpScMpGnlzr8a38cafutkCtcmE60H7hZ8d1dX9cz6YdtnJ-XwxXOLHhz8mZRbPAWDN8AS-VyGy66aSjhSPQ0B6tQy2cSKx65lSiRFTo9C3TZ2Qm5XBKTJ6c982ow0M_PaL-szv_hU8-OY8u3sDrpSHJTvsF78JWrN_C_FdTRdaUrKLiZyw0i8imkUDT7WzBvrEZZYNERiwghEBn-FQUc-V-Yy9eVgTSYG3Hd165PimpPmGnjAIKODEtBQfM_yZovoPbi_Obs3GyrKmQFEKJNtGZz5ywzhujeMHR_ytSZ3SwuNGN8twLW3CrAi9FxoU3Vishg4smph59vyj2YLtu6vgBWOpidFlwgTsjU5c69HfNyJW6CB6_Wm4AX1dizOc9dUZOLgcJPZ-WOcm7b0joAzhaSTpHDaffFq6OzeMi58SRZDj6lQN430t-PZ_Qhsq38wFkG-9kPYDYszd7UKk6Fu2lEn189p2HsDO-mVzlV9-vL_fhFdWh72Mzn2C7fXiMB2ittP5zp5t_AJNe6Rg |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3da9swEBddC6Uvo6Xrln5Ng70N17G-LPctbRfS9YMyVuibkSyZBBzbLC70z--dnaTJ-rYXgZEsi_PJujv_7neEfHfSCm4U7G84-wLhZRZolrtAWO0VS1TOGWYj392r0aP49SSfVkp9taD9zE7OymJ6Vk7GLbaynmbhAicWPtxdJmAW6ESHtcvDD2RLclCydUcdrBwOxnZ_GW5hSGTVsaciLaIEx2-eQiNiIcIxsnky1jX9FhO9eky9sz3_hVCunEnDXfJxbkzSQbfoPbLhy31S_64KT6ucFlgAjbpq5unYI3C6mczoBZ1gRoinyASCKHQKTwVRF-YFeuGyQKAGbVrO88J0iUnlOR1QDCrAxLgUGFC_JWl-Io_Dn38uR8G8rkKQccmbQMU2NjwxVmvJMgY-YBYZrVwCm11LyyxPMpZIx3IeM251oiQXznjtIwv-n-cHZLOsSv-F0Mh4b2JnHDNaRCYy4PPqvslV5ix8uUyP_FiIMa07-owU3Q4UejrOU5R316DQe-TbQtIpaDn-ujClr55nKUOeJM3At-yRz53kl_NxpbGEO-uReO2dLAcgg_Z6DyhWy6Q9V6TD_77zK9l-uBqmt9f3N0dkB0vRd-GZY7LZ_H32J2CwNPa0Vc1X9FDqKw |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Role+of+lower+dose+hepatitis+B+immune+globulin+prophylaxis+in+liver+transplantation%3A+A+single+center+perspective&rft.jtitle=Hepatology+forum&rft.au=Edwards%2C+Diep&rft.au=Lin%2C+Jessica&rft.au=Toman%2C+Lindsey&rft.au=Gurakar%2C+Merve&rft.date=2023-01-01&rft.eissn=2757-7392&rft.volume=4&rft.issue=1&rft.spage=3&rft_id=info:doi/10.14744%2Fhf.2022.2022.0030&rft_id=info%3Apmid%2F36843892&rft.externalDocID=36843892 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1307-5888&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1307-5888&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1307-5888&client=summon |